637 related articles for article (PubMed ID: 33547304)
1. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.
Yang R; Sun L; Li CF; Wang YH; Yao J; Li H; Yan M; Chang WC; Hsu JM; Cha JH; Hsu JL; Chou CW; Sun X; Deng Y; Chou CK; Yu D; Hung MC
Nat Commun; 2021 Feb; 12(1):832. PubMed ID: 33547304
[TBL] [Abstract][Full Text] [Related]
2. TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas.
Li Z; Liu X; Guo R; Wang P
Tumour Biol; 2017 May; 39(5):1010428317698352. PubMed ID: 28475007
[TBL] [Abstract][Full Text] [Related]
3. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
4. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
5. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8
Cagnoni AJ; Giribaldi ML; Blidner AG; Cutine AM; Gatto SG; Morales RM; Salatino M; Abba MC; Croci DO; Mariño KV; Rabinovich GA
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006646
[TBL] [Abstract][Full Text] [Related]
6. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
[TBL] [Abstract][Full Text] [Related]
7. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C.
Kared H; Fabre T; Bédard N; Bruneau J; Shoukry NH
PLoS Pathog; 2013; 9(6):e1003422. PubMed ID: 23818845
[TBL] [Abstract][Full Text] [Related]
8. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
9. Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells.
Veenstra RG; Taylor PA; Zhou Q; Panoskaltsis-Mortari A; Hirashima M; Flynn R; Liu D; Anderson AC; Strom TB; Kuchroo VK; Blazar BR
Blood; 2012 Jul; 120(3):682-90. PubMed ID: 22677125
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.
Zhou K; Guo S; Tong S; Sun Q; Li F; Zhang X; Qiao Y; Liang G
Stem Cells Dev; 2018 Sep; 27(17):1191-1202. PubMed ID: 29978730
[TBL] [Abstract][Full Text] [Related]
11. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.
Nagahara K; Arikawa T; Oomizu S; Kontani K; Nobumoto A; Tateno H; Watanabe K; Niki T; Katoh S; Miyake M; Nagahata S; Hirabayashi J; Kuchroo VK; Yamauchi A; Hirashima M
J Immunol; 2008 Dec; 181(11):7660-9. PubMed ID: 19017954
[TBL] [Abstract][Full Text] [Related]
12. Rational design of anti-GITR-based combination immunotherapy.
Zappasodi R; Sirard C; Li Y; Budhu S; Abu-Akeel M; Liu C; Yang X; Zhong H; Newman W; Qi J; Wong P; Schaer D; Koon H; Velcheti V; Hellmann MD; Postow MA; Callahan MK; Wolchok JD; Merghoub T
Nat Med; 2019 May; 25(5):759-766. PubMed ID: 31036879
[TBL] [Abstract][Full Text] [Related]
13. Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma.
Huang L; Xu Y; Fang J; Liu W; Chen J; Liu Z; Xu Q
Front Immunol; 2021; 12():654749. PubMed ID: 33936081
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P; Bhattacharya P; Prabhakar BS
J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
[TBL] [Abstract][Full Text] [Related]
15. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
[TBL] [Abstract][Full Text] [Related]
16. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
[TBL] [Abstract][Full Text] [Related]
17. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
Zhou Q; Munger ME; Veenstra RG; Weigel BJ; Hirashima M; Munn DH; Murphy WJ; Azuma M; Anderson AC; Kuchroo VK; Blazar BR
Blood; 2011 Apr; 117(17):4501-10. PubMed ID: 21385853
[TBL] [Abstract][Full Text] [Related]
19. PTPN2 regulates the generation of exhausted CD8
LaFleur MW; Nguyen TH; Coxe MA; Miller BC; Yates KB; Gillis JE; Sen DR; Gaudiano EF; Al Abosy R; Freeman GJ; Haining WN; Sharpe AH
Nat Immunol; 2019 Oct; 20(10):1335-1347. PubMed ID: 31527834
[TBL] [Abstract][Full Text] [Related]
20. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
